Company Short-Term Debts: Kineta Bio (KA)

Graphic logo of Kineta, Inc. (KA)

This daily price chart for Kineta, Inc. (KA) reflects a situation where management is attempting to find ways to monetize developments following the cessation of key research. Business stability relies on licensing patent rights to industry behemoths to maintain liquidity. However, the 0.00 metric highlights a crisis: due to a funding shortage, the workforce has been reduced, and seeking buyers for intellectual property has become the priority.

KA: Kineta Inc Short-Term Debt 04/28/2023 - 09/28/2024

Kineta Corp - analytical breakdowns and key metrics (KA)

- price and consensus price forecast:
Price Chart Kineta|KA - Average Forecast Price
- market capitalization data:
Market Capitalization Kineta, Inc.|KA - Full Takeover Company Value
- book capitalization data:
Accounting Value per Share Kineta|KA - Total Stockholders' Equity|Market Cap to Net Assets Ratio kinetabio.com|KA - Aggregate Asset Value
- debt and liquidity data:
Total Debt to Capital Kineta, Inc.|KA - Ratio of Long-Term Indebtedness to Capital|Short-Term Debt to Equity Kineta, Inc.|KA - Company Total Debt|Debt to Book Capitalization Ratio Kineta, Inc.|KA - Company Long-Term Liabilities|Company Current Liabilities Kineta
Fundamental company valuation:Kineta - KA
Product sample of Kineta, Inc.

The development of immuno-oncology drugs by Kineta, Inc. requires significant R&D expenditures, making liquidity control critical for business survival. This total short-term debt aggregates all obligations maturing within one year, allowing investors to assess default risk or the issuer's readiness for aggressive scaling via leveraged capital.

Competitor analysis

IBRX (ImmunityBio) - Company Short-Term Debt|IMCR - Short-Term Debt|Company Short-Term Debts JANX (Janux Pharma)|Short-Term Indebtedness Arcus Corp|Company Current Liabilities ZYME (Zymeworks Inc.)|Short-Term Debt tangotx.com (TNGX)|Iovance Biotherapeutics, Inc. (IOVA) - Company Current Liabilities|Company Short-Term Loans and Borrowings Immatics NV (IMTX)|Company Short-Term Debts XNCR|Compass Therapeutics Corp - Short-Term Debt Volume|REPL: Company Short-Term Debt|LYEL: Company Current Liabilities|IPHA (Innate Pharma) - Company Short-Term Debt|Company Current Liabilities Pyxis Oncology|CGEN (Compugen Ltd) - Company Current Liabilities|Company Short-Term Debts IOBT|Company Short-Term Debt Sutro Biopharma, Inc. STRO|Company Short-Term Indebtedness INKT (minktherapeutics.com)|HOWL: Company Short-Term Debt|IMMX - Short-Term Debt|Company Current Liabilities ALXO|Cue Biopharma Inc. (CUE) - Short-Term Indebtedness|PDSB - Company Current Liabilities|Sonnet BioTherapeutics Holdings (SONN) - Amount of Current Liabilities|MAIA - Company Short-Term Debts|Company Short-Term Loans and Borrowings Liminatus Pharma Inc.|LAVA Therapeutics N.V. - Company Short-Term Debts|Short-Term Debt NXTC (NextCure Corporation)|Company Short-Term Debt Leap Therapeutics|Company Short-Term Loans and Borrowings Intensity Therapeutics Inc INTS|Sensei Bio - Company Short-Term Debts|TOVX: Company Short-Term Debts|Company Short-Term Debt gritstonebio.com (GRTS)|Current Liabilities NexImmune Corporation|Company Current Liabilities TSBX (Turnstone Biologics Corp)|Short-Term Debt VCNX|Company Short-Term Debt HARP